1-6 of 6
Koichi Azuma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation

Open Access
Shintaro Kanda, Seiji Niho, Takayasu Kurata, Shogo Nomura, Yosuke Kawashima, Eiji Iwama, Toshihide Yokoyama, Yasutaka Watanabe, Hiroshi Tanaka, Yutaka Fujiwara, Yoshitaka Zenke, Koichi Azuma, Hirokazu Taniguchi, Ryo Toyozawa, Yukio Hosomi, Haruyasu Murakami, Satoshi Hara, Akihiro Bessho, Nobuyuki Yamamoto, Yuichiro Ohe
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12): 2317–2326.
https://doi.org/10.1158/1078-0432.CCR-24-3532
Published: 13 June 2025
View articletitled, Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
Open the PDF for Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Open Access
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 893–902.
https://doi.org/10.1158/1078-0432.CCR-21-3194
Published: 01 March 2022
View articletitled, A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Open the PDF for A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) in another window
Includes: Supplementary data
Journal Articles

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

Free
Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi, Takuma Irie, Katsunori Tatsugami, Tomoaki Hoshino, Masatoshi Eto, Hiroyoshi Nishikawa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4808–4819.
https://doi.org/10.1158/1078-0432.CCR-18-3991
Published: 01 August 2019
View articletitled, Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Open the PDF for Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Free
Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, Masayoshi Kage, Tomoaki Hoshino, Yoichi Nakanishi, Isamu Okamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 4014–4021.
https://doi.org/10.1158/1078-0432.CCR-15-0016
Published: 31 August 2015
View articletitled, Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Open the PDF for Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis

Free
Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashihara, Hisamichi Aizawa, Yuji Basaki, Michihiko Kuwano, Masayoshi Kage, Tetsuya Mitsudomi, Mayumi Ono
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (12): 3163–3170.
https://doi.org/10.1158/1078-0432.CCR-09-3239
Published: 14 June 2010
View articletitled, Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Open the PDF for Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis in another window
Journal Articles

Ran , a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients

Free
Koichi Azuma, Tetsuro Sasada, Hiroko Takedatsu, Hiroki Shomura, Makoto Koga, Yoshiaki Maeda, Akihisa Yao, Tatsuya Hirai, Arimichi Takabayashi, Shigeki Shichijo, Kyogo Itoh
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6695–6702.
https://doi.org/10.1158/1078-0432.CCR-04-0818
Published: 08 October 2004
View articletitled, Ran , a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients
Open the PDF for Ran , a Small GTPase Gene, Encodes Cytotoxic T Lymphocyte (CTL) Epitopes Capable of Inducing HLA-A33–restricted and Tumor-Reactive CTLs in Cancer Patients in another window